Singapore markets closed

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.92+0.09 (+1.54%)
At close: 04:00PM EDT
6.00 +0.08 (+1.35%)
Pre-market: 08:21AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 501.08M
Enterprise value 361.69M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.71
Enterprise value/revenue N/A
Enterprise value/EBITDA -5.54

Trading information

Stock price history

Beta (5Y monthly) 0.63
52-week change 3-26.00%
S&P500 52-week change 323.23%
52-week high 310.45
52-week low 33.25
50-day moving average 34.24
200-day moving average 35.48

Share statistics

Avg vol (3-month) 31.17M
Avg vol (10-day) 3957.26k
Shares outstanding 584.64M
Implied shares outstanding 684.64M
Float 882.05M
% held by insiders 13.05%
% held by institutions 137.92%
Shares short (28 Jun 2024) 417.83M
Short ratio (28 Jun 2024) 412.93
Short % of float (28 Jun 2024) 421.73%
Short % of shares outstanding (28 Jun 2024) 421.06%
Shares short (prior month 31 May 2024) 421.82M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 307 Oct 2015

Financial highlights

Fiscal year

Fiscal year ends 30 Sept 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-19.63%
Return on equity (ttm)-28.98%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-40.59M
Diluted EPS (ttm)-0.50
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)139.39M
Total cash per share (mrq)1.65
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)15.12
Book value per share (mrq)1.61

Cash flow statement

Operating cash flow (ttm)-32.48M
Levered free cash flow (ttm)-21.69M